News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

Wednesday, 18. November 2015

Category

Publications

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

Published

Wednesday, 03. June 2015

Category

PARI Publications

In-vitro Study of Aerosolised Colistin Delivered to the Nasal Tract via a Pulsating Aerosol Delivery Device (Vibrent®).

In-vitro Study of Aerosolised Colistin Delivered to the Nasal Tract via a Pulsating Aerosol Delivery Device (Vibrent®).

Published

Friday, 01. August 2014

Category

Publications

Drug delivery to paranasal sinuses using pulsating aerosols.

Drug delivery to paranasal sinuses using pulsating aerosols.

Published

Friday, 20. June 2014

Category

Publications

A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.

A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.

Published

Wednesday, 18. June 2014

Category

PARI Publications

The eFlow ‘‘closed system’’(CS) - a novel device platform for liquid aerosol drug-device combinations.

The eFlow ‘‘closed system’’(CS) - a novel device platform for liquid aerosol drug-device combinations.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team